Antineoplastic Agents, Alkylating
"Antineoplastic Agents, Alkylating" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)
| Descriptor ID |
D018906
|
| MeSH Number(s) |
D27.505.519.124.035 D27.505.954.248.150 D27.888.569.035.035
|
| Concept/Terms |
Antineoplastic Agents, Alkylating- Antineoplastic Agents, Alkylating
- Alkylating Antineoplastic Agents
- Alkylating Antineoplastic Drugs
- Alkylating Antineoplastics
- Antineoplastic Alkylating Agents
- Antineoplastic Drugs, Alkylating
- Antineoplastics, Alkylating
- Alkylating Agents, Antineoplastic
- Alkylating Drugs, Antineoplastic
- Antineoplastic Alkylating Drugs
- Drugs, Antineoplastic Alkylating
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Alkylating".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Alkylating".
This graph shows the total number of publications written about "Antineoplastic Agents, Alkylating" by people in this website by year, and whether "Antineoplastic Agents, Alkylating" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 3 | 3 |
| 1998 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 1 | 2 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2009 | 4 | 0 | 4 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 1 | 2 |
| 2012 | 3 | 0 | 3 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 3 | 2 | 5 |
| 2018 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 1 | 2 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Alkylating" by people in Profiles.
-
Dose-escalated accelerated hypofractionation for elderly or frail patients with a newly diagnosed glioblastoma. J Neurooncol. 2022 Jan; 156(2):399-406.
-
Regulation of autophagy as a therapeutic option in glioblastoma. Apoptosis. 2021 12; 26(11-12):574-599.
-
Dual Encapsulated Dacarbazine and Zinc Phthalocyanine Polymeric Nanoparticle for Photodynamic Therapy of Melanoma. Pharm Res. 2021 Feb; 38(2):335-346.
-
Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. J Neurol Sci. 2020 Nov 15; 418:117102.
-
MGMT-inhibitor in combination with TGF-?RI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells. Clin Transl Oncol. 2021 Mar; 23(3):612-619.
-
Novel approach to temozolomide resistance in malignant glioma: connexin43-directed therapeutics. Curr Opin Pharmacol. 2018 08; 41:79-88.
-
Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus. 2016 Sep 01; 53(5):275-84.
-
Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma. Pituitary. 2016 Aug; 19(4):415-21.
-
Combined-Modality Therapy With Radiation and Chemotherapy for Elderly Patients With Glioblastoma in the Temozolomide Era: A National Cancer Database Analysis. JAMA Neurol. 2016 07 01; 73(7):821-8.
-
Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers. Nanomedicine (Lond). 2016 Mar; 11(6):581-95.